Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)

Eric Hedrick,Herbert Hurwitz,Somnath Sarkar,Susan Griffing,William Novotny,A. Grothey

Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)

2004

Eric Hedrick
Herbert Hurwitz
Somnath Sarkar
Susan Griffing
William Novotny
A. Grothey

3517 Background: Bevacizumab [Avastin (BV)], a recombinant humanized monoclonal antibody against VEGF, significantly prolongs overall survival (OS) when added to 1st-line chemotherapy for mCRC. BV ...

Keywords:

Bevacizumab
Physical therapy
Colorectal cancer
Cancer research
Oncology
Internal medicine
Medicine
first line treatment
Monoclonal antibody
Chemotherapy
VEGF receptors
overall survival
Recombinant DNA

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations